M1 Kliniken AG’s nine-month Beauty EBIT rises 35.5% to EUR 28.6 million

M1 Kliniken AG

/ Key word(s): 9 Month figures/Change in Forecast

M1 Kliniken AG’s nine-month Beauty EBIT rises 35.5% to EUR 28.6 million

18.11.2026 / 08:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


M1 Kliniken AG’s nine-month Beauty EBIT rises 35.5% to EUR 28.6 million

Berlin, 18 November 2026 – M1 Kliniken AG (ISIN: DE000A0STSQ8) reported EBIT of EUR 28.6 million in its Beauty segment for the first nine months of 2026. This already exceeds the EUR 28.3 million the segment earned in the whole of 2025. The EBIT margin rose to 33.0% from 27.1% in the same period last year.

Beauty segment delivers further growth and higher profitability

  • Revenue: up 11.3% to EUR 86.6 million (9M 2025: EUR 77.8 million)
  • EBIT: up 35.5% to EUR 28.6 million (9M 2025: EUR 21.1 million)
  • EBIT margin: 33.0% (9M 2025: 27.1%)

EBIT grew even faster in the third quarter:

  • Revenue: up 11.7% to EUR 29.7 million (Q3 2025: EUR 26.6 million)
  • EBIT: up 63.9% to EUR 10.0 million (Q3 2025: EUR 6.1 million)
  • EBIT margin: 33.7% (Q3 2025: 22.9%)

Group earnings and margins rise year on year

  • Group revenue: EUR 106.3 million (9M 2025: EUR 274.3 million)
  • EBITDA: up 1.5% to EUR 28.7 million (9M 2025: EUR 28.2 million)
  • EBIT: up 4.6% to EUR 25.6 million (9M 2025: EUR 24.5 million)
  • EBIT margin: 24.1% (9M 2025: 8.9%)
  • Adjusted EBIT: up 21.1% to EUR 29.7 million (9M 2025: EUR 24.5 million)
  • EBT: up 7.0% to EUR 26.1 million (9M 2025: EUR 24.4 million)
  • Earnings per share: up 5.6% to EUR 0.91 (9M 2025: EUR 0.86)

The Group figures are only partly comparable with the prior year. M1 Aesthetics AG (formerly HAEMATO AG), in which the Group holds an 85% stake, sold HAEMATO Pharm GmbH with effect from the close of 31 January 2026. As a result, the figures include the Trading segment for only one month, compared with nine months in the prior-year period. This accounts for the entire decline in Group revenue.

Group EBIT includes a one-off non-cash charge of EUR 4.1 million from the deconsolidation. Adjusted for this charge, EBIT reached EUR 29.7 million, up 21.1% year on year. Third-quarter earnings per share were EUR 0.38 (Q3 2025: EUR 0.23).

Group completes planned exit from the Trading segment

  • Revenue: EUR 19.7 million (9M 2025: EUR 196.5 million)
  • EBIT: EUR −3.0 million (9M 2025: EUR 3.4 million)

All Trading segment revenue was generated in January 2026, the final month before the sale. Segment EBIT includes the EUR 4.1 million deconsolidation charge. Since the sale, the Group has focused exclusively on the Beauty segment.

Outlook

The Management Board has raised its medium-term margin target. By 2029, the Group aims to generate revenue of EUR 200 million to EUR 300 million in the Beauty segment at a sustainable EBIT margin of at least 25% (previously at least 20%). To reach these targets, M1 plans to open further clinics in Germany and abroad. The Heilbronn clinic is scheduled to open on 1 December 2026, bringing the network to 60 clinics. Further openings are planned for 2027. In the longer term, the Group aims to establish M1 Med Beauty as the world’s leading brand in aesthetic medicine.

The Company plans to move its listing from the Open Market to the Prime Standard of the Frankfurt Stock Exchange in 2027. It remains committed to its stable dividend policy. The Company announced the higher margin target and the planned move in an ad hoc announcement yesterday evening.

“Our business model scales. Both in Germany and abroad, we are carrying out more treatments and expanding our medical capacity,” said Attila Strauss, CEO of M1 Kliniken AG. “Moving to the Prime Standard will make our shares accessible to a broader range of institutional investors.”

About M1 Kliniken AG

M1 Kliniken AG is the leading fully integrated provider of aesthetic medical services in Europe and Australia. Under the M1 Med Beauty brand, the Group operates 59 clinics in ten countries using a focused, highly standardised and scalable business model. All treatments are performed by qualified doctors to the same high quality standards and are offered at market-leading prices. The Group has pursued international expansion since the end of 2018 to support further growth and strengthen its global market position. In Berlin, the Group operates M1 Schlossklinik, one of Europe’s largest and most modern clinics for aesthetic plastic surgery. The clinic has four operating theatres and 35 beds.

Contact:
M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
T: +49 (0)30 347 47 44 14
M: ir@m1-kliniken.de


18.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Germany
Phone: +49 (0)30 347 47 44 14
Fax: +49 (0)30 347 47 44 17
E-mail: ir@m1-kliniken.de
Internet: https://www.m1-kliniken.de
ISIN: DE000A0STSQ8
WKN: A0STSQ
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 529900W697S31A26WT02
EQS News ID: 2437242

 
End of News EQS News Service

2437242  18.11.2026 CET/CEST

Ellipses Pharma explores a London Stock Exchange listing opportunity

Ellipses Pharma explores a London Stock Exchange listing opportunity




Ellipses Pharma explores a London Stock Exchange listing opportunity

LONDON–(BUSINESS WIRE)–Ellipses Pharma Limited (“Ellipses”) the London-based global oncology drug development company with a pipeline of innovative programmes, today announced that the Company is exploring a listing opportunity on the main market of the London Stock Exchange.


Ellipses has signed a non-binding Memorandum of Understanding (“MoU”) with Wolfram Resources Plc (LSE: WFR) (“Wolfram”) a main market listed special purpose acquisition company whose ordinary shares are traded on the Equity Shares (Shell Companies) listing category. The MoU is intended to result in a reverse takeover through the proposed acquisition of the entire issued share capital of Ellipses by Wolfram and the re-listing of the enlarged group on the Main Market on the Equity Shares (Commercial Companies) category.

Since its establishment in 2017, Ellipses has focused on identifying, acquiring and advancing promising oncology assets through clinical development. The proposed transaction with Wolfram provides a potential public market platform from which to support the continued development of its portfolio, broaden access to capital and create opportunities for long-term value generation for its shareholders.

Ellipses’ portfolio spans multiple clinical-stage programmes, with trial sites across the United States, Europe and Asia Pacific. This includes EP0031 (lunbotinib), a next-generation selective RET inhibitor in Phase 2 development for RET-altered non-small cell lung cancer, partnered with Kelun-Biotech, and EP0062 (vosilasarm), an oral selective androgen receptor modulator in Phase 2 development in ER+/HER2- breast cancer.

Proposed Transaction

The consideration for the proposed transaction with Wolfram is expected to be satisfied through the issue of new ordinary shares in Wolfram, with final terms to be agreed following due diligence. An equity fundraising is also expected to be undertaken in conjunction with the Proposed Transaction.

Ellipses and Wolfram will now commence a period of due diligence and work towards agreeing definitive transaction documentation and final terms, with completion currently targeted for early 2027. There can be no certainty that the Proposed Transaction will proceed or as to the final terms on which it may proceed.

Professor Sir Chris Evans OBE, Founder and Chair of Ellipses Pharma, said:

“Our company has been focused resolutely on the development of promising drug candidates and the progress made with our pipeline, including encouraging results from our clinical trials for both EP0031 and EP0062, which indicates that this is now the optimal time to move towards a public listing. We also see our main market listing as a shot in the arm for the UK Life Sciences sector which has a great scientific pedigree.

“The proposed transaction with Wolfram will accelerate Ellipses’ plan to deliver the next stage of our evolution as a public company. Opting to list through a reverse takeover process has recently become more common in the Life Sciences sector and will enable us to raise additional capital from public company investors. This will drive progress within our portfolio, broaden access to capital and allow our current shareholders to realise growth in the longer term. We look forward to working with the Wolfram team to deliver the transaction.

Graeme Muir, Executive Director of Wolfram Resources Plc, said:

“We are excited to be working with such a strong management team that brings with it years of experience and a proven track record. We now move to detailed due diligence, and we believe this transaction can deliver real value for Wolfram shareholders.”

Further information

Further information about Ellipses Pharma is available at www.ellipses.life.

Contacts

media@ellipses.life
Ramsay Smith, Media House International

+44 (0) 7788 414856

Verfora acquires majority stake in distribution partner Qpharma

Verfora is acquiring a majority stake in the Polish pharmaceutical distributor Qpharma. With the acquisition of 51% of the shares, Verfora is expanding its distribution network to include a long-standing distribution partner and thus an established distribution platform. At the same time, the company is gaining an important partner along its own value chain and thus, alongside Austria, a second distribution network in Europe. The combination of strong brands, marketing expertise and local distribution know-how creates additional development opportunities for its existing consumer healthcare business.

Established distribution platform

Qpharma is a family-run company based in Poland that has been active in the healthcare market for over 20 years and generated sales in the low double-digit million euro range. The company specialises in marketing, promotion and distribution of prescription-only drugs, OTC products and dietary supplements. Qpharma has exclusive distribution rights for various brands in Poland, the Czech Republic and Slovakia.

Qpharma has built up an established market position in Eastern Europe and has long-standing customer relationships as well as extensive experience in marketing and distribution of healthcare products. The company has been working with Verfora for many years and is responsible for the distribution of various Verfora products, including Perskindol in Poland and the Czech Republic and, since 2025, Padma products in Poland.

Acquisition of a long-standing partner

The acquisition brings together Verfora’s brand and marketing expertise with Qpharma’s established distribution platform and expands Verfora’s value chain. Qpharma’s attractive distribution licences also offer further development potential. Following the acquisition, Qpharma will continue to be managed by the current CEO, Zbyszek Czop, and developed together with Verfora.

“Qpharma has been an important partner for our brands for many years with an excellent understanding of our products, quality standards and its customers’ needs. With this acquisition, we are further developing a successful collaboration and creating the conditions to make even better use of our combined potential,” says Stefan Wälti, CEO of Verfora.

Completion of the transaction is subject to regulatory approvals. The parties have agreed not to disclose the sale price.

Avenzo Therapeutics Presents Positive Preliminary Results from the Phase 1 Study of AVZO-1418, a Potentially Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium

Avenzo Therapeutics Presents Positive Preliminary Results from the Phase 1 Study of AVZO-1418, a Potentially Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium




Avenzo Therapeutics Presents Positive Preliminary Results from the Phase 1 Study of AVZO-1418, a Potentially Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium

Pan-tumor potential with responses across six dose levels and five of eight tumor types (EGFRm NSCLC, UC, CRC, SCCHN, NSCLC-WT)

63% ORR in a pretreated EGFRm NSCLC population, the majority of whom were 3rd line or later; multiple responses ≥24 weeks

Favorable safety profile demonstrated with low incidence of Grade 3/4 hematologic TEAEs (6% neutrophil count decreased, 4% anemia) at doses up to 5.5 mg/kg every two weeks

Rapid development plan with global expansion to pursue monotherapy and combinations in multiple tumor types ongoing

SAN DIEGO–(BUSINESS WIRE)–Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced positive preliminary clinical data from the Phase 1 portion of the Phase 1/2 AVENTINE-1 study evaluating AVZO-1418 in patients with locally advanced or metastatic solid tumors. The data highlight the pan-tumor potential of AVZO-1418 with objective responses observed across five of eight tumor types. Preliminary efficacy data also showed an objective response rate (ORR) of 63% in 19 evaluable patients with heavily pretreated epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), the majority of whom were in 3rd line or later. AVZO-1418 also demonstrated a favorable safety profile with a low incidence of Grade 3/4 hematologic adverse events. The data are being presented as a poster at the 38th EORTC-NCI-AACR Symposium in Barcelona, Spain, on November 18, 2026, from 12:00 p.m. to 7:00 p.m. CET.


“AVZO-1418 has shown encouraging preliminary activity across multiple tumor types, pointing to its potential as a pan-tumor therapy,” said Dr. Stephen Liu, Division Chief of Hematology/Oncology at MedStar Georgetown University Hospital, part of the MedStar Georgetown Cancer Institute. “I am especially encouraged by the strong efficacy signal and tolerability of AVZO-1418 in patients with EGFR-mutant NSCLC, the majority of whom received a prior 3rd generation EGFR TKI and platinum-based chemotherapy and have limited next options.”

Clinical Data for AVENTINE-1, Phase 1/2 Study of AVZO-1418

As of the October 19, 2026 data cutoff, 61 patients with advanced solid tumors had received AVZO-1418 in the Phase 1 dose-escalation and backfill portion of the Phase 1/2 AVENTINE-1 study at doses of 2 to 6 mg/kg every two weeks (Q2W) or 6 mg/kg every three weeks (Q3W).

Patients included those with NSCLC-wild-type (NSCLC-WT) (n=20), EGFR-mutant NSCLC (EGFRm NSCLC) (n=19), colorectal cancer (CRC) (n=6), biliary tract cancer (BTC) (n=4), squamous cell carcinoma of the head and neck (SCCHN) (n=4), urothelial cancer (UC) (n=3), and other solid tumors (n=5). The backfill portion of the study was enriched for EGFRm NSCLC based on the strong early efficacy signal.

All patients (n=61) had received a median of two prior lines of systemic therapy in the advanced or metastatic setting (range 1 to 6), with 41% having received two prior lines of systemic therapy and 34% having received three or more prior lines. 84% of patients had received platinum-based chemotherapy and 54% had received anti-PD-(L)1 immunotherapy.

Patients with EGFRm NSCLC (n=19) had received a median of two prior lines of systemic therapy in the advanced or metastatic setting (range 1 to 4), with 47% having received two prior lines of systemic therapy and 16% having received three or more prior lines. 58% of patients had received platinum-based chemotherapy and all had received a prior 3rd generation EGFR tyrosine kinase inhibitor (TKI). At baseline, 63% of patients had an exon 19 deletion and 32% had an exon 21 L858R mutation.

Preliminary Safety Results

The overall safety population included 61 patients, with 48 patients treated at 2 to 5.5 mg/kg Q2W dose levels and 13 patients treated at 6 mg/kg Q2W and Q3W dose levels.

AVZO-1418 was generally well tolerated in the 2 to 5.5 mg/kg Q2W group (n=48)

  • No dose-limiting toxicities (DLTs) were observed.
  • Treatment-emergent adverse events (TEAEs) reported in >20% of patients were nausea, alopecia, fatigue, anemia, vomiting, stomatitis, headache, constipation, and decreased appetite. The majority of these events were Grade 1 or 2.
  • Anemia and neutrophil count decreased were reported as TEAEs in 33% and 19% of patients, with Grade 3/4 events reported in 4% and 6%, respectively.
  • Prophylactic granulocyte colony-stimulating factor (G-CSF) was not required in the study.

The 6 mg/kg dose level, dosed by actual body weight, exceeded the maximum tolerated dose (MTD) on both the Q2W and Q3W schedules, with two DLTs reported in each cohort.

Preliminary Efficacy Results

Preliminary efficacy data were available for 48 evaluable patients with measurable disease at baseline and at least one evaluable post-baseline scan. An additional seven patients remained on treatment and had not yet reached a post-baseline scan at the data cutoff date, and six patients were off treatment prior to an evaluable post-baseline scan for reasons other than disease progression.

Data are as of the cutoff date of October 19, 2026, with efficacy follow-up through November 5, 2026.

Responses were assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The ORRs reported below include confirmed partial responses and unconfirmed partial responses in patients who remain on treatment awaiting confirmatory scans.

Preliminary efficacy results across all tumor types suggest pan-tumor potential (n=48)

  • Responses were observed across six dose levels in five of eight tumor types (EGFRm NSCLC, UC, CRC, SCCHN, NSCLC-WT).
  • ORR was 38% (18 of 48 patients; 95% confidence interval (CI), 24.0%–52.6%), including 16 patients with confirmed partial responses (one patient with CRC confirmed their response after the efficacy follow up date), and two patients with unconfirmed partial responses who remained on treatment awaiting confirmatory scans.
  • 26 of 48 patients remained on treatment as of the data cutoff date, including 17 of 18 responders.
  • 13 patients had been on treatment for 24 weeks or longer.

Strong efficacy signal in patients with EGFRm NSCLC, majority of whom were previously treated with both a 3rd generation EGFR TKI and platinum-based chemotherapy (n=19)

  • ORR was 63% (12 of 19 patients; 95% CI, 38.4%–83.7%), including 10 patients with confirmed partial responses and two with unconfirmed partial responses who remained on treatment awaiting confirmatory scans, with multiple responses for 24 weeks or longer.
  • 100% of patients achieved tumor reduction on their first post-baseline scan.
  • 15 of 19 patients remained on treatment as of the data cutoff date, including:

    • 11 responders.
    • Four patients with tumor reductions (three with >20% reduction from baseline) awaiting their next scans.
  • Responses were observed across five dose levels.

“We believe the preliminary data for AVZO-1418, with responses in five of eight tumor types, support its potential as a broadly active, pan-tumor therapy,” said Mohammad Hirmand, M.D., Co-founder and Chief Medical Officer of Avenzo Therapeutics. “We’re particularly excited by the strong signal in EGFR-mutant NSCLC, where patients urgently need new treatment options. We are pursuing a rapid development plan that includes global expansion and further evaluation in multiple tumor types, with the goal of bringing this potentially transformative therapy to patients as quickly as possible.”

About AVZO-1418

AVZO-1418 is a potentially best-in-class EGFR/HER3 bispecific antibody-drug conjugate (ADC) in development for locally advanced or metastatic solid tumors. It is designed with higher binding affinity for HER3 than EGFR to enhance delivery of its topoisomerase I inhibitor payload to EGFR/HER3-expressing tumors while limiting effects on healthy tissue. This dual-targeting approach may support activity across multiple tumor types, including EGFR-mutant non-small cell lung cancer. AVZO-1418 is being evaluated as monotherapy in the Phase 1 portion of the Phase 1/2 AVENTINE-1 study, with combination regimens also planned. Avenzo holds exclusive global rights, excluding Greater China, from DualityBio to develop, manufacture and commercialize AVZO-1418.

About Avenzo Therapeutics

Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. The company’s pipeline includes potentially differentiated small molecules and bispecific antibody-drug conjugates (ADCs). Avenzo’s small molecule inhibitors, AVZO-021 and AVZO-023, are novel, highly potent and selective inhibitors of CDK2 and CDK4, respectively, which are key enzymes involved in cell cycle regulation. AVZO-021 has completed enrollment in a Phase 1 study as monotherapy in advanced solid tumors and in combination with fulvestrant in HR+/HER2- metastatic breast cancer. AVZO-021 and AVZO-023 are being evaluated in the Phase 1/2 ORION-1 study in HR+/HER2- metastatic breast cancer, where AVZO-023 is administered in combination with endocrine therapy, with or without AVZO-021. Avenzo’s first ADC drug candidate, AVZO-1418, is a potentially differentiated EGFR/HER3 bispecific ADC that is being studied in the AVENTINE-1 Phase 1/2 study for the treatment of advanced solid tumors. Avenzo’s second ADC drug candidate, AVZO-103, is a potentially differentiated Nectin4/TROP2 bispecific ADC that is being studied in the BEACON-1 Phase 1/2 study for the treatment of advanced solid tumors. Avenzo is headquartered in San Diego, California. For more information, visit us at www.avenzotx.com or on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding the potential therapeutic benefits, clinical activity, safety, tolerability and differentiation of AVZO-1418; AVZO-1418’s potential as a broadly active, pan-tumor therapy, including in EGFR-mutant NSCLC; the potential for AVZO-1418’s dual-targeting design to enhance tumor-selective payload delivery while limiting effects on healthy tissue; the development strategy for AVZO-1418, including the pace of development, geographic expansion and ongoing and planned evaluation as monotherapy and in combination regimens across multiple tumor types; the potential to obtain FDA approval and to bring new treatment options to patients; the potential differentiation and continued development of Avenzo’s oncology pipeline; and other statements that are not historical facts. Forward-looking statements are based on Avenzo’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include the early-stage nature of Avenzo’s clinical programs; the risk that preliminary results from small patient populations may change with additional patients and longer follow-up and may not be predictive of subsequent results; the risk that unconfirmed responses may not be confirmed and that observed responses may not be durable; the risk that additional or more severe adverse events, including dose-limiting toxicities, may emerge; the risk that the proposed mechanism of action or observed clinical activity may not translate into a differentiated safety or efficacy profile or clinical benefit across tumor types; delays or difficulties in initiating, enrolling, expanding or completing clinical trials, including combination studies and studies in additional countries; the risk that ongoing or planned trials may not demonstrate adequate safety and efficacy to support continued development or regulatory approval; Avenzo’s dependence on collaboration partners and other third parties for development, manufacturing and clinical trial activities; and Avenzo’s ability to obtain sufficient funding to advance its product candidates. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Avenzo expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contacts

Avenzo Therapeutics Contacts:

Annie Chang

Investor Relations

achang@avenzotx.com

Carla Taub

Media Relations

ctaub@avenzotx.com

CAI Enters Into a Definitive Agreement with PQE Group, Expanding Global Life Sciences Reach

CAI Enters Into a Definitive Agreement with PQE Group, Expanding Global Life Sciences Reach




CAI Enters Into a Definitive Agreement with PQE Group, Expanding Global Life Sciences Reach

CAI and PQE Group will pair complementary CQV and CSV expertise to support life sciences clients worldwide.

INDIANAPOLIS–(BUSINESS WIRE)–CAI, a professional services firm dedicated to accelerating operational readiness and excellence in life sciences and mission-critical environments, has entered into a definitive agreement with PQE Group, a global life sciences quality, compliance and validation consulting firm headquartered in Florence, Italy. The partnership will position the company to serve clients navigating complex, highly regulated environments around the world.


The strategic alignment will bring together CAI’s expertise in commissioning, qualification and validation (CQV), operational readiness and operational excellence with PQE Group’s complementary expertise in computer system validation (CSV), quality and compliance. The combined organization will have an expanded presence across North America, Europe, Latin America and Asia-Pacific, providing clients with connected support across the manufacturing lifecycle.

“For 30 years, CAI has been committed to helping our clients bring life-changing products to patients with confidence and speed,” said CAI CEO Sheena Dempsey. “PQE Group shares that commitment, and we have tremendous respect for what Gilda D’Incerti and her team have built over the past 28 years. By bringing together the strengths of both organizations, we have an exciting opportunity to build on our respective legacies and deliver even greater value to the clients and industries we serve.”

The agreement builds on the growth capital and strategic flexibility CAI gained through its 2026 recapitalization with JLL Partners, a New York-based middle-market private equity firm, and advances the expansion strategy CAI outlined at the time of that investment.

About CAI

CAI is a professional services firm composed of engineering, quality and operations experts dedicated to accelerating Operational Readiness and Operational Excellence in life sciences and mission-critical environments. With deep roots in CQV (commissioning, qualification, validation), CAI has evolved over the past 30 years alongside the industries it serves, helping organizations bring complex facilities, systems and technologies online with confidence. For more information, please visit caiready.com.

About PQE Group

PQE Group is a global life sciences consulting firm headquartered in Florence, Italy, offering quality, compliance, validation and digital innovation services to pharmaceutical, biotech, and medical device companies, with a strong presence across Europe, Latin America and APAC. For more information, please visit www2.pqegroup.com.

This transaction remains subject to regulatory approvals and customary closing conditions.

Contacts

Media Contact

Carrie Cash for CAI: Carrie.Cash@caiready.com

Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026

Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026




Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026

  • Encouraging tolerability profile with stomatitis as the only dose-limiting toxicity; low overall hematologic toxicity, consistent with low circulating free-exatecan levels, supporting linker stability
  • Antitumor activity observed across tumor types, including in post-enfortumab vedotin urothelial cancer; ORR of 33% (2/6) at the maximum tolerated dose of 3.6 mg/kg Q3W in non-urothelial tumors
  • Initiating dose optimization with first patient planned in H1 2027, to further characterize safety and activity in post-EV urothelial cancer at upper dose levels and define a recommended Phase 2 dose and schedule
  • Following the poster presentation at ENA (poster), Innate will host an in-person and virtual key opinion leader (KOL) event focused on IPH4502, today at 11:00 a.m. ET / 4:00 p.m. GMT (webcast link)

MARSEILLE, France–(BUSINESS WIRE)–#ADC–Regulatory News:


Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced initial Phase 1 data from its ongoing study of IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate (ADC) incorporating an exatecan payload, in patients with advanced solid tumors. The results are being presented today at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026).

“The Phase 1 findings provide an encouraging foundation for the continued development of IPH4502,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “The observed antitumor activity and safety profile strengthen our commitment to advancing this program, particularly for patients with urothelial cancer previously treated with enfortumab vedotin, where significant unmet need remains. Our focus now is on optimizing the dose and schedule to further characterize antitumor activity and tolerability in this setting and inform selection of a recommended Phase 2 regimen.”

Study Population and Background

The Phase 1 dose-escalation study of IPH4502 enrolled 76 patients with advanced solid tumors across six dose levels ranging from 0.6 mg/kg to 3.6 mg/kg, administered once every three weeks. Patients were heavily pretreated, with a median of 3.5 prior lines of systemic therapy and represented more than 10 tumor types. Nineteen patients had urothelial cancer (UC), all of whom had previously received PADCEV® (enfortumab vedotin). The primary objective of the study was to assess the safety and tolerability of IPH4502, while secondary objectives include evaluating its pharmacokinetics and antitumor activity in patients with advanced solid tumors.

Safety and Tolerability

As of the August 17, 2026 data cutoff, IPH4502 was well-tolerated during Phase 1 dose escalation, with low overall hematologic toxicity.

  • The maximum tolerated dose was established at 3.6 mg/kg administered once every three weeks, with stomatitis as the only reported dose-limiting toxicity. No febrile neutropenia or hematologic dose-limiting toxicities were reported, and no signal of peripheral neuropathy was observed.
  • Grade 3 or higher treatment-emergent adverse events (TEAEs) were reported in 43.4% of patients, including Grade 3 or higher anemia in 11.8%. Stomatitis occurred in 27.6% of patients overall, including 3.9% with Grade 3 or higher events.
  • TEAEs led to dose reductions in 7.9% of patients and treatment discontinuations in 5.3%.

Antitumor Activity

As of the August 17, 2026 data cutoff, antitumor activity (measured using RECIST v1.1 criteria) was observed across multiple dose levels, tumor types and Nectin-4 expression levels.

  • Objective responses were observed in patients in several tumor types and across low, moderate and high Nectin-4 expression levels.
  • At the maximum tolerated dose of 3.6 mg/kg, an objective response rate (ORR) of 33% (2/6) was observed in patients with non-urothelial tumors.
  • In urothelial cancer, 19 patients were enrolled, with a median of three prior lines of systemic therapy; all had previously received enfortumab vedotin. Out of these 19 patients, 15 were enrolled at 2.4 or 2.8 mg/kg, 4 at 3.2 mg/kg and none at 3.6 mg/kg (MTD). At these intermediate dose levels, antitumor activity was observed, with 3 partial responses (1 confirmed and 2 unconfirmed partial responses) and tumor shrinkage in the majority of patients. The unconfirmed disease control rate [95%CI] was 68.4% [46.0 – 84.6].

Future Clinical Development Strategy

Phase 1 dose optimization is being initiated in second-line or later urothelial cancer following enfortumab vedotin, to further characterize safety and activity in post-EV urothelial cancer at upper dose levels. The first patient is planned in the first half of 2027. The study will evaluate split dosing on Days 1 and 8 of each three-week cycle with mandatory prophylaxis to help reduce stomatitis and inform selection of a recommended Phase 2 dose and schedule.

ENA Presentation and KOL Event

Following the presentation of Phase 1 IPH4502 data at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on November 18, 2026, Innate will host an in-person and virtual key opinion leader (KOL) event the same day at 11:00 a.m. ET / 4:00 p.m. GMT to discuss the results, their clinical context and the planned next steps of IPH4502 development (press release). The event will take place at IET London: Savoy Place, with a live webcast available through the following registration link: https://lifescievents.com/event/inz37gy/

About IPH4502

IPH4502 is Innate Pharma’s proprietary Nectin-4 antibody-drug conjugate (ADC), built on three differentiated components. The payload is exatecan, a potent topoisomerase I inhibitor, with the potential to overcome key limitations associated with monomethyl auristatin E (MMAE)-based ADCs, including multidrug resistance protein 1 (MDR1)-mediated resistance. IPH4502 incorporates a proprietary stable linker designed to slow the release of free exatecan into the circulation in order to improve tolerability. The binder is a proprietary humanized anti-Nectin-4 antibody with high affinity and a distinct, non-overlapping epitope compared with enfortumab vedotin (EV). IPH4502 is currently being evaluated in the Phase 1 IPH4502-101 study (NCT06781983) in patients with advanced solid tumors known to express Nectin-4. Initial clinical data from the Dose escalation phase (ENA 2026 poster) showed antitumor activity across multiple tumor types, including urothelial cancer previously treated with enfortumab vedotin, alongside an encouraging tolerability profile with low overall hematologic toxicity. Phase 1 dose optimization is being initiated in second-line or later urothelial cancer following enfortumab vedotin.

IPH4502 is currently under clinical development and has not received marketing authorization in the European Union or approval from the U.S. Food and Drug Administration (FDA). Its safety and efficacy have not been established for any commercial use. The product is not available for commercial distribution.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first- and/or best-in-class assets, focused on areas of high unmet medical need. Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors, and supported by a preclinical portfolio of next-generation ADC candidates. In parallel, Innate is advancing two partnered late-stage assets: lacutamab, developed with Sobi for T-cell lymphomas, and monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC).

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sobi, Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code

Ticker code

LEI

FR0010331421

Euronext: IPH Nasdaq: IPHA

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “plan,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although Innate believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development, including the trading price and volatility of Innate’s ADSs and Ordinary Shares and risks related to Innate’s business and financial performance. For additional discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

Stéphanie Cornen VP,

Investor Relations & Corporate Communications

stephanie.cornen@innate-pharma.fr

Investor Relations

investors@innate-pharma.fr

Media

communication@innate-pharma.fr

Shionogi Completes Acquisition of IntraBio Inc. and Adds AQNEURSA® (levacetylleucine) to Growing Rare Disease Global Portfolio

Shionogi Completes Acquisition of IntraBio Inc. and Adds AQNEURSA® (levacetylleucine) to Growing Rare Disease Global Portfolio




Shionogi Completes Acquisition of IntraBio Inc. and Adds AQNEURSA® (levacetylleucine) to Growing Rare Disease Global Portfolio

AQNEURSA is approved in the U.S. and Europe for neurological manifestations of Niemann-Pick disease type C and in the U.S. as the first and only treatment for Ataxia in patients diagnosed with Ataxia-Telangiectasia

Shionogi is committed to seamless continuity of care for patient communities in the U.S. and to achieving access in Europe

OSAKA, Japan–(BUSINESS WIRE)–Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that it has completed the acquisition of IntraBio Inc. (“IntraBio”). The acquisition adds AQNEURSA® (levacetylleucine) and additional rare disease capabilities to Shionogi’s growing global portfolio.


AQNEURSA was approved by the U.S. Food and Drug Administration in 2024 and by the European Medicines Agency (EMA) in January 2026 for neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing at least 15 kg in the U.S. and 20 kg in Europe.1,2 The FDA approved AQNEURSA as the first and only option for the treatment of Ataxia in adults and pediatric patients diagnosed with Ataxia-Telangiectasia (A-T) weighing at least 15 kg in September 2026.3

AQNEURSA is currently under review by the EMA for adult and pediatric patients diagnosed with A-T and it is currently being studied for the treatment of CACNA1A disorders in a Phase III, randomized, placebo-controlled, double-blind, crossover study. Shionogi will continue programs initiated by IntraBio and explore additional opportunities to research AQNEURSA in additional rare disease conditions.

“With the closing of the IntraBio acquisition, we welcome AQNEURSA to Shionogi’s growing portfolio and strengthen our global capabilities with additional rare disease expertise,” said Isao Teshirogi, Ph.D., CEO of Shionogi. “For nearly 150 years, Shionogi has grown our business by adapting to the changing needs of patients. This milestone is the latest representation of our steadfast commitment to deliver innovative medicines to protect the health and wellbeing of the patients we serve.”

Under the terms of the agreement announced on October 5, 2026, Shionogi Inc., a New Jersey-based subsidiary of Shionogi, paid a lump sum of USD 2.0 billion to acquire all outstanding shares of IntraBio, including global intellectual property and commercialization rights for AQNEURSA.

“Through acquisitions, integrations and strategic hires, Shionogi is building a strong, sustainable rare disease presence with a clear purpose: to make a meaningful difference for patients,” said Nathan McCutcheon, President and CEO, Shionogi Inc. “We have the infrastructure, portfolio, and commitment to deliver the medicines, patient support and services, and the scientific expertise and determination to advance new treatment options for tomorrow.”

“We look forward to partnering with patient groups representing people living with these devastating conditions, and learning from patients, families and carers about the challenges they face and how we can best help improve their lives,” said Huw Tippett, CEO, Shionogi Europe.

“We look forward to partnering with the Shionogi team. The recent U.S. regulatory approval of AQNEURSA, the first targeted treatment for A-T, has brought hope to many children and their families. With the additional reach and resources that Shionogi brings, we are hopeful that more A-T families will be able to access this treatment,” said Brad Margus, Founder, A-T Children’s Project.

“For the Niemann-Pick community, this acquisition is an opportunity to build on progress to date for people living with NPC and their families. We are deeply grateful to IntraBio for securing approval for AQNEURSA and their support of our community. We look forward to working with Shionogi to expand access and ensure this important therapy reaches the families who need it most,” said Heather Teal, Executive Director, National Niemann-Pick Disease Foundation.

Following the acquisition of RADICAVA ORS® (edaravone) earlier this year, a treatment for amyotrophic lateral sclerosis (ALS), Shionogi has established a strong commercial and medical affairs foundation in rare disease, including expertise serving patients with neurodegenerative diseases. Bringing IntraBio to Shionogi expands that foundation with new capabilities to support the company’s growing rare disease pipeline, which includes clinical programs in Pompe disease, Fragile X syndrome and Jordan’s syndrome, as well as additional early-stage rare neurodegenerative disease programs.

About AQNEURSA®

AQNEURSA® is approved in the U.S. for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing at least 15 kg, and for the treatment of ataxia in adult and pediatric patients diagnosed with Ataxia-Telangiectasia (A-T) weighing at least 15 kg. In Europe, it has also been approved for the treatment of neurological manifestations of NPC in adults and pediatric patients aged 6 years and older weighing at least 20 kg in combination with miglustat, or as monotherapy in patients where miglustat is not tolerated. AQNEURSA is currently under review by the EMA for adults and pediatric patients diagnosed with Ataxia-Telangiectasia (A-T).

IMPORTANT SAFETY INFORMATION

Before taking AQNEURSA, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.

  • Based on findings from animal reproduction studies, AQNEURSA may cause harm to your unborn baby when administered during pregnancy.
  • Your healthcare provider will check to make sure you are not pregnant before starting treatment with AQNEURSA.
  • Use effective birth control (contraception) during treatment with AQNEURSA and for 7 days after stopping treatment to avoid pregnancy.
  • If you become pregnant while taking AQNEURSA, inform your healthcare provider immediately to discuss potential risks and alternative treatments.
  • It is not known if AQNEURSA or its metabolites pass into human or animal milk or effect breastmilk production.

Tell your healthcare provider about all the medications you take and if you get any new medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Other medicines may cause side effects or affect how AQNEURSA works when used together.

  • Tell your healthcare provider if you are taking certain medications called P-gp substrates, N-acetyl-DL-leucine or N-acetyl-D-leucine. If you are not sure if you are taking these medicines, talk to your healthcare provider or pharmacist.

The most common side effects of AQNEURSA in people treated for Niemann-Pick disease type C include abdominal pain, dysphagia, upper respiratory tract infections and vomiting.

The most common side effects of AQNEURSA in people treated for ataxia-telangiectasia include fall, skin laceration, and urinary tract infection.

These are not all the possible side effects of AQNEURSA. Call your doctor for medical advice about side effects. You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

About Niemann-Pick Disease Type C

Niemann-Pick disease type C (NPC) is an ultra-rare, progressive and life-limiting autosomal recessive lysosomal storage disorder caused by variants in the NPC1 or NPC2 genes.4,5 These variants impair the movement of cholesterol and other lipids within cells, leading to their accumulation in the brain and other organs.4,5 NPC can cause a broad range of neurological and systemic symptoms that significantly impair daily functioning.5 Symptoms may begin at any age, from infancy through adulthood, and the disease’s variable presentation can contribute to delayed diagnosis. NPC has an estimated incidence of approximately one case per 100,000 live births.5

About Ataxia-Telangiectasia

Ataxia-Telangiectasia (A-T) is a rare, inherited and progressive neurodegenerative disease caused by variants in the ATM gene that typically begins in early childhood.6 A-T is estimated to affect approximately one in 40,000 to 100,000 live births worldwide.6 The disease causes worsening problems with movement, coordination, speech and eye movements, and many people develop visible dilated blood vessels known as telangiectasias.6 A-T can also impair immune function and cause recurrent infections and serious pulmonary complications. A-T is associated with a markedly increased risk of cancer, particularly leukemia and lymphoma, and significantly reduced life expectancy.6

About Shionogi & Co., Ltd.

Shionogi & Co., Ltd. is a 148-year-old global, research-driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain and CNS disorders. Shionogi’s research and development currently targets infectious diseases and diseases with unmet medical needs, including rare diseases, allergy/inflammation, oncology, hearing loss, and sleep apnea. For more information on Shionogi & Co., Ltd., please visit https://www.shionogi.com/global/en.

About Shionogi Inc.

Shionogi Inc. is a U.S. subsidiary of Shionogi & Co., Ltd., a global research-driven pharmaceutical company. Today in North America, our FDA-approved infectious disease portfolio includes an antibiotic for serious infections caused by susceptible Gram-negative bacteria and an oral antiviral for post-exposure prophylaxis of COVID-19. Our FDA-approved rare disease portfolio includes therapies for amyotrophic lateral sclerosis (ALS), Niemann-Pick disease type C (NPC) and Ataxia in patients diagnosed with Ataxia-Telangiectasia (A-T). Our pipeline programs include investigational treatments across infectious disease, rare disease and additional high-need therapeutic areas. Together with our subsidiaries Qpex Biopharma Inc. and Shionogi Canada Inc., we are continuing to innovate for patients in the U.S. and worldwide. Learn more at shionogi.com.

About Shionogi B.V.

Shionogi B.V. is the European subsidiary of Shionogi & Co., Ltd., a global, research-driven pharmaceutical company headquartered in Osaka, Japan. In Europe, Shionogi is dedicated to bringing benefits to patients by advancing innovative medicines in areas of significant unmet medical need. Our work focuses on infectious diseases and rare diseases, building on Shionogi’s long-standing expertise in infectious diseases and growing commitment to addressing rare conditions. Shionogi also works with stakeholders across the healthcare ecosystem to support public health and strengthen health security in Europe. For more information about Shionogi in Europe, please visit https://www.shionogi.com/eu/en/.

About Shionogi in Rare Disease

Shionogi is committed to changing the trajectory of rare disease. Our mission is to transform the lives of people living with rare diseases by advancing breakthrough science into transformative medicines. We focus on areas where patients face profound unmet needs, bringing together scientific innovation, a focused development approach, and a deep commitment to patients, families and communities. Today Shionogi is delivering a meaningful therapy for patients living with amyotrophic lateral sclerosis (ALS) and, through ongoing research and development, is advancing the next generation of rare disease medicines.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

References

  1. AQNEURSA® (levacetylleucine) Full Prescribing Information. IntraBio Inc. Revised 9/2026. Accessed November 17, 2026. https://www.aqneursa.com/wp-content/prescribing-information.pdf
  2. European Medicines Agency. Aqneursa, INN-levacetylleucine. Summary of Product Characteristics. Accessed November 17, 2026. https://www.ema.europa.eu/en/documents/product-information/aqneursa-epar-product-information_en.pdf
  3. U.S. Food and Drug Administration. FDA Approves Therapy to Treat Ataxia in Patients with Ataxia-Telangiectasia, a Rare Genetic Disorder. Accessed November 17, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-therapy-treat-ataxia-patients-ataxia-telangiectasia-rare-genetic-disorder
  4. Wassif, C.A., et al. High incidence of unrecognized visceral/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. Genetics in Medicine. 2016; 18:41–48. Accessed November 17, 2026. https://www.sciencedirect.com/science/article/pii/S1098360021042921?via%3Dihub
  5. Hiwot, T., et al. 2025 Consensus Clinical Management Guidelines for Niemann-Pick Disease Type C. Journal of Inherited Metabolic Disease. 2026; 49:e70185. Accessed November 17, 2026. https://doi.org/10.1002/jimd.70185
  6. Rothblum-Oviatt C., et al. Ataxia telangiectasia: a review. Orphanet Journal of Rare Diseases. 2016; 11:159. Accessed November 17, 2026. https://ojrd.biomedcentral.com/articles/10.1186/s13023-016-0543-7

Contacts

For Further Information, Contact:
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
U.S. Media: ShionogiCommunications@shionogi.com
Shionogi Europe Press Office: pressoffice@shionogi.eu

M1 Kliniken AG plans move to the Prime Standard in 2027 and raises EBIT margin target for its Beauty segment to at least 25%

M1 Kliniken AG / Key word(s): Strategic corporate decision/Forecast / Other

M1 Kliniken AG plans move to the Prime Standard in 2027 and raises EBIT margin target for its Beauty segment to at least 25%

17-Nov-2026 / 23:13 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014

M1 Kliniken AG plans move to the Prime Standard in 2027 and raises EBIT margin target for its Beauty segment to at least 25%

Berlin, 17 November 2026 – The Management Board of M1 Kliniken AG (ISIN: DE000A0STSQ8) resolved this evening, with the approval of the Supervisory Board, to prepare the transfer of the listing of the Company’s shares from the Open Market (Basic Board) to the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange. Admission is planned for 2027 and is subject to the admission requirements being met.

The Management Board has also raised its target for a sustainable EBIT margin in the Beauty segment by 2029 from at least 20% to at least 25%. The segment’s revenue target of EUR 200 million to EUR 300 million by 2029 remains unchanged.

Contact:
Attila Strauss, Katharina Zimmnau, Management Board
Corporate Communications
E-Mail: ir@m1-kliniken.de

End of Inside Information


17-Nov-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Germany
Phone: +49 (0)30 347 47 44 14
Fax: +49 (0)30 347 47 44 17
E-mail: ir@m1-kliniken.de
Internet: https://www.m1-kliniken.de
ISIN: DE000A0STSQ8
WKN: A0STSQ
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 529900W697S31A26WT02
EQS News ID: 2437226

 
End of Announcement EQS News Service

2437226  17-Nov-2026 CET/CEST

Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer

Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer




Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer

  • Approval based on phase I/II ALKOVE-1 trial demonstrating clinically meaningful and durable responses in pretreated patients
  • Next-generation ALK inhibitor designed to help address resistance, disease in the brain and tolerability challenges
  • GSK’s second approval in lung cancer this year1

PHILADELPHIA–(BUSINESS WIRE)–#ALK—GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has granted accelerated approval to Nelkarmi (neladalkib) for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received the following therapy in the unresectable locally advanced or metastatic setting: one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy.2


This approval comes ahead of the original FDA target action date of November 27, 2026 and follows the FDA’s Breakthrough Therapy and Orphan Drug designations.3

Tony Wood, Chief Scientific Officer, GSK said: “Nelkarmi is our second new medicine approved in lung cancer this year. It was designed to help address key challenges of ALK-positive non-small cell lung cancer through its broad coverage of ALK resistance mutations, ability to cross the blood-brain barrier and high target selectivity. ALK-positive patients are often younger and can remain on treatment for years, making effective and tolerable new treatment options especially important, and we are pleased to bring this innovation to patients in the US.”

The approval is based on results from the phase I/II ALKOVE-1 trial. For patients previously treated with alectinib as their only prior ALK TKI, the confirmed overall response rate (ORR) was 49% (33/67; 95% CI: 37%, 62%), with a duration of response (DOR) as assessed by blinded independent central review (BICR) of 6 or more months in 76% of responders and 12 or more months in 52% of responders. For patients with two or more prior ALK TKIs and chemotherapy, the ORR was 32% (50/155; 95% CI: 24%, 40%), with DOR of 6 or more months in 69% of responders and 12 or more months in 51% of responders.2

Among patients with measurable central nervous system (CNS) metastases at baseline, intracranial ORR was 55% (11/20; 95% CI: 32%, 77%) (including 25% complete responses) in those previously treated with alectinib as their only prior ALK TKI, and 26% (14/53; 95% CI: 15%, 40%) (including 11% complete responses) in those who had received two or more prior ALK TKIs and chemotherapy.2

The most common (≥20%) adverse reactions were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue. Permanent discontinuation of Nelkarmi due to adverse reactions occurred in 5% of patients. The most frequent adverse reaction that led to permanent discontinuation was hepatotoxicity.2

Alice Shaw, MD, PhD, an ALKOVE-1 trial investigator, Chair of the Department of Medical Oncology and Chief of Strategic Partnerships at Dana-Farber Cancer Institute, said: “Patients with ALK-positive lung cancer are often treated with multiple targeted therapies over many years. Advances in treatment have brought us closer to the goal of managing ALK-positive lung cancer as a chronic condition, but balancing disease control and long-term tolerability remains a significant challenge. The approval of neladalkib provides an important new treatment option for patients.”

Kirk Smith, President, ALK Positive, said: “For people living with ALK-positive lung cancer, one of the hardest moments is learning that a treatment that had been working is no longer controlling the disease. As patients move through multiple therapies over the course of their disease, they need options that balance durable disease control with the ability to tolerate and remain on treatment and maintain quality of life. Today’s approval represents important progress for our community.”

Nelkarmi, part of the portfolio from the recent acquisition of Nuvalent, Inc., is also being evaluated in ALKAZAR, an ongoing phase III trial in TKI-naïve ALK-positive NSCLC, and in other solid tumors.

About Nelkarmi (neladalkib)

Nelkarmi is an ALK-selective tyrosine kinase inhibitor (TKI) approved for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received the following therapy in the unresectable locally advanced or metastatic setting: one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy.

It was designed to help address treatment resistance and disease that has spread to the brain, key challenges in ALK-positive NSCLC and other cancers.

Indication and Important Safety Information for NELKARMI (neladalkib)

NELKARMITM (neladalkib) is indicated for the treatment of adult patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have previously received the following therapy in the unresectable locally advanced or metastatic setting:

  • 1 prior ALK TKI consisting of alectinib; or
  • 2 or more prior ALK TKIs and platinum-based chemotherapy

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS:

Warnings and Precautions reflect the pooled safety population (N=700) of patients enrolled in ALKOVE-1, who received NELKARMI at a dose of 150 mg orally once daily until disease progression or unacceptable toxicity.

Hepatotoxicity:

  • NELKARMI can cause severe and life-threatening hepatotoxicity, including drug induced liver injury (DILI) resulting in hepatic failure.
  • Hepatotoxicity occurred in 56% of patients who received NELKARMI; of these, 18% were Grade 3 and 7% were Grade 4. Grade 3 or 4 DILI occurred in 0.3% of patients and Grade 3 or 4 hepatic failure occurred in 0.4% of patients.
  • Increased alanine aminotransferase (ALT) occurred in 62% of patients, including Grade 3 in 13% and Grade 4 in 4.8%. Increased aspartate aminotransferase (AST) occurred in 63%, including Grade 3 in 11% and Grade 4 in 2.5% of patients.
  • NELKARMI was interrupted due to hepatotoxicity in 25%, the dose was reduced in 11% and permanently discontinued in 3% of patients.
  • Monitor liver function tests (ALT, AST, and total bilirubin) at baseline, every 2 weeks during the first 2 months of treatment, and then monthly and as clinically indicated, with more frequent testing in patients who develop transaminase elevations. Withhold, then resume at the same dose or reduced dose, or permanently discontinue NELKARMI based on severity.

Renal Toxicity:

  • NELKARMI can cause severe and life-threatening renal toxicity including acute kidney injury.
  • Acute kidney injury occurred in 1.1%, including Grade 3 in 0.3%, Grade 4 in 0.3%. Grade 2 chronic kidney disease occurred in 0.3% of patients.
  • Increased serum creatinine occurred in 24%, including Grade 3 in 0.1% and Grade 4 in 0.3% of patients.
  • NELKARMI was interrupted for renal toxicity in 0.6% and permanently discontinued in 0.4% of patients.
  • Monitor serum creatinine at baseline and every 2 weeks for the first month and then periodically as clinically indicated during treatment. Withhold, then resume at the same or reduced dose or permanently discontinue NELKARMI based on severity.

Ocular Toxicity:

  • NELKARMI can cause ocular toxicity including retinal detachment, corneal erosion, and keratopathy.
  • Ocular toxicity occurred in 14%. Grade 2 ocular toxicity occurred in 2.9%, Grade 3 (diplopia, retinal detachment, corneal erosion, and keratopathy) was observed in one patient each and Grade 4 (retinal detachment) was observed in one patient.
  • NELKARMI was interrupted in 0.7% of patients due to ocular toxicity.
  • Monitor for vision changes at regular intervals during treatment with NELKARMI. Promptly refer patients with new or worsening visual symptoms to an eye care professional, such as an ophthalmologist or optometrist. Withhold, then reduce the dose or permanently discontinue NELKARMI based on severity.

Creatinine Phosphokinase (CPK) Elevation:

  • NELKARMI can cause severe CPK elevation.
  • Increased CPK occurred in 28%, including Grade 3 in 2.7% and Grade 4 in 1.2% of patients.
  • NELKARMI was interrupted for CPK elevation in 1.9%, and the dose was reduced in 0.4% of patients.
  • Monitor serum CPK levels at baseline and every 2 weeks for the first 2 months, then periodically as clinically indicated during treatment with NELKARMI. Withhold, then resume at the same or reduced dose, or permanently discontinue NELKARMI based on severity.

Embryo-Fetal Toxicity:

  • Based on literature reports in humans with congenital mutations leading to changes in tropomyosin receptor kinase (TRK) signaling, findings from animal studies, and its mechanism of action, NELKARMI can cause fetal harm when administered to a pregnant woman.
  • Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective nonhormonal contraception during treatment with NELKARMI and for 2 weeks after the last dose.
  • Advise males with female partners of reproductive potential to use effective contraception during treatment with NELKARMI and for 2 weeks after the last dose.

ADVERSE REACTIONS:

The serious and fatal adverse reactions reflect exposure to NELKARMI in 656 patients with ALK-positive NSCLC enrolled in ALKOVE-1.

  • Serious adverse reactions occurred in 30% of patients who received NELKARMI. Serious adverse reactions reported in ≥2% of patients included hepatotoxicity (7%), pneumonia (3.7%), pleural effusion (2.4%) and dyspnea (2.3%).
  • Fatal adverse reactions occurred in 1.1% of patients who received NELKARMI, including cardiac arrest (0.3%), pulmonary embolism (0.2%), sudden death (0.2%), pneumonia (0.2%), aspiration pneumonia (0.2%), and shock hemorrhagic (0.2%).

The most common adverse reactions (≥20%) and most common Grade 3 or 4 laboratory abnormalities (≥2%) reflect exposure to NELKARMI in the pooled safety population (N=700) of patients enrolled in ALKOVE-1.

  • The most common adverse reactions (≥20%) were hepatotoxicity (56%), musculoskeletal pain (33%), constipation (28%), dysgeusia (24%), peripheral neuropathy (23%), edema (21%), and fatigue (21%).
  • The most common Grade 3 or 4 laboratory abnormalities (≥2%), were increased ALT (18%), increased AST (13%), increased CPK (3.9%), decreased lymphocytes (2.5%), decreased potassium (2.3%), and decreased hemoglobin (2.3%).

DRUG INTERACTIONS:

Strong and Moderate CYP3A Inhibitors:

  • Avoid concomitant use of NELKARMI with strong or moderate CYP3A inhibitors, as this may increase neladalkib plasma concentrations, which may increase the risk of NELKARMI-associated adverse reactions.

Strong and Moderate CYP3A Inducers:

  • Avoid concomitant use of NELKARMI with strong or moderate CYP3A inducers, as this may decrease neladalkib plasma concentrations and may decrease the effectiveness of NELKARMI.

The US Prescribing information will be available here.

About the ALKOVE-1 trial

ALKOVE-1 (NCT05384626) is a global single-arm phase I/II trial evaluating neladalkib in patients with advanced ALK-positive NSCLC and other ALK-positive solid tumors. The trial enrolled 700 patients with ALK-positive solid tumors across the phase I and phase II portions. The primary efficacy analysis supporting the FDA approval included 222 patients with previously treated ALK-positive NSCLC. The major efficacy outcome measures were confirmed overall response rate (ORR) and duration of response (DOR) as assessed by blinded independent central review.

About NSCLC

NSCLC is the most common form of lung cancer and is often characterized by specific genetic alterations, such as those in ALK, ROS1 or HER2. It can often metastasize (i.e. spread) to the central nervous system. It primarily affects working-age individuals. Current treatments may have efficacy and/or tolerability limitations that leave unmet need for patients.

About GSK in oncology

GSK is focused on developing differentiated medicines for cancers where patients continue to face poor outcomes, treatment resistance, limited options or significant treatment burden. We focus where advances in science and technology offer the greatest opportunity to improve outcomes across hematological, lung, gastrointestinal, genitourinary and gynecological cancers. Across multiple modalities, including targeted small molecules, antibody-drug conjugates (ADCs) and immunotherapies, GSK applies deep expertise in cancer biology and immune system science to develop differentiated medicines designed to deliver durable responses, overcome resistance and reduce treatment burden.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2025, and GSK’s Q3 Results for 2026.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

References 

____________________________________
 
1 GSK press release, Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer, July 2026

2 Nelkarmi (neladalkib) US Prescribing Information. November 2026.

3 Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC – Apr 7, 2026

 

Contacts

GSK enquiries
Media:

Tim Foley +44 (0) 20 8047 5502 (London)

Sarah Clements +44 (0) 20 8047 5502 (London)

Kathleen Quinn +1 202 603 5003 (Washington DC)

Alison Hunt +1 540 742 3391 (Washington DC)

Investor Relations:

James Dodwell +44 (0) 7881 269066 (London)

Mick Readey +44 (0) 7990 339653 (London)

Joanna Tuplin +44 (0) 7788 351650 (London)

Sam Piper +44 (0) 7824 525779 (London)

Dan Smith +44 (0) 7823 523885 (London)

Jeff McLaughlin +1 215 751 7002 (Philadelphia)

Frannie DeFranco +1 215 751 3126 (Philadelphia)

Octant Appoints Eddy Anglade, M.D., as Chief Medical Officer

Octant Appoints Eddy Anglade, M.D., as Chief Medical Officer




Octant Appoints Eddy Anglade, M.D., as Chief Medical Officer

Ophthalmology drug development leader joins to advance OCT-980 and further develop clinical capabilities supporting Octant’s pipeline


EMERYVILLE, Calif.–(BUSINESS WIRE)–Octant, Inc., a clinical-stage drug discovery company developing corrector therapies for protein misfolding diseases, today announced the appointment of Eddy Anglade, M.D., as its first Chief Medical Officer. Dr. Anglade will lead Octant’s clinical development strategy, including advancing its lead program, OCT-980 for rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP).

“OCT-980 is the first molecule from our platform to reach patients, and more are coming behind it,” said Sri Kosuri, co-founder and Chief Executive Officer of Octant. “Eddy has led development from first-in-human studies through late-stage programs, and he is the right person to lead these programs through the clinic and get them to the patients who need them.”

Dr. Anglade brings more than 20 years of experience leading drug development across ophthalmology, rare disease and regenerative medicine. He most recently served as Chief Executive Officer of Tenpoint Therapeutics. Previously, he was Vice President and Clinical Lead, Retina at Janssen Research & Development, where he led strategy for its development-stage retinal programs. At Astellas Pharma, he served as Global Therapeutic Area Head, Ophthalmology, having joined through its acquisition of Ocata Therapeutics, where he was Chief Medical Officer. He also co-founded Lux Biosciences and served as its Chief Medical Officer. Dr. Anglade received his M.D. from Yale University School of Medicine and completed his ophthalmology residency at Massachusetts Eye and Ear/Harvard Medical School, with additional training at the National Eye Institute.

“Patients with RHO-adRP have no approved therapies. OCT-980 addresses the root cause of their disease,” said Dr. Anglade. “I am thrilled to join Octant and look forward to leading the clinical development of OCT-980 as we work to change that.”

About Octant

Octant is a clinical-stage drug discovery company developing small-molecule correctors for protein misfolding diseases. Octant’s platform, The Navigator, combines high-throughput synthetic biology, scaled chemistry, and AI/ML to discover and develop therapeutics against complex cellular mechanisms in human cells. The company’s pipeline is led by OCT-980, an investigational oral small molecule currently being evaluated in a Phase 1b/2 clinical trial for rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP). Octant’s pipeline also includes programs across other rare diseases and oncology. For more information, visit www.octant.bio.

Contacts

Tarek Saoud

(510) 224-4321

press@octant.bio